The ETS transcription factor MEF is a candidate tumor suppressor gene on the X chromosome

Cancer Research

Volumn 62, Issue 22, 2002, Pages 6579-6586

  Seki, Yoshiyuki ^a   Ann Suico, Mary ^a   Uto, Ayako ^a   Hisatsune, Akinobu ^a   Shuto, Tsuyoshi ^a   Isohama, Yoichiro ^a   Kai, Hirofumi ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; BATIMASTAT; CD31 ANTIGEN; GELATINASE A; GELATINASE B; INTERLEUKIN 8; MATRIX METALLOPROTEINASE INHIBITOR; MESSENGER RNA; MYELOID ELF 1 LIKE FACTOR; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ETS 2; UNCLASSIFIED DRUG;

ANGIOGENESIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CONTACT; CHROMOSOME XQ; CONTROLLED STUDY; EMBRYO; GENE TRANSFER; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE; UMBILICAL VEIN; UPREGULATION; VASCULAR ENDOTHELIUM; WESTERN BLOTTING; X CHROMOSOME;

ANIMALS; CACO-2 CELLS; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HELA CELLS; HUMANS; INTERLEUKIN-8; MATRIX METALLOPROTEINASE 9; MICE; MICE, NUDE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROMOTER REGIONS (GENETICS); RNA, MESSENGER; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TRANSFECTION; UP-REGULATION; X CHROMOSOME;

EID: 0037112510     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Knudson, A. G., Jr., Hethcote, H. W., and Brown, B. W. Mutation and childhood cancer: A probabilistic model for the incidence of retinoblastoma. Proc. Natl. Acad. Sci. USA, 72: 5116-5120, 1975.
2. Klein, C. B. Conway, K., Wang, X. W., Bhamra, R. K., Lin, X. H., Cohen, M. D., Annab, L., Barrett, J. C., and Costa, M. Senescence of nickel-transformed cells by an X chromosome: Possible epigenetic control. Science (Wash. DC), 251: 796-799, 1991.
3. Sakurazawa, N., Tanaka, N., Onda, M., and Esumi, H. Instability of X chromosome methylation in aberrant crypt foci of the human colon. Cancer Res., 60: 3165-3169, 2000.
4. Conway, K., and Costa, M. Nonrandom chromosomal alterations in nickel-transformed Chinese hamster embryo cells. Cancer Res. 49: 6032-6038, 1989.
5. Choi, C., Cho, S., Horikawa, I., Berchuck, A., Wang, N., Cedrone, E., Jhung, S. W., Lee, J. B., Kerr, J., Chenevix-Trench, G., Kim, S., Barrett, J. C., and Koi, M. Loss of heterozygosity at chromosome segment Xq25-26.1 in advanced human ovarian carcinomas. Genes Chromosomes Cancer, 20: 234-242, 1997.
6. Choi, C., Kim, M. H., and Juhng, S. W. Loss of heterozygosity on chromosome XP22.2-p22.13 and Xq26.1-q27.1 in human breast carcinomas. J. Korean Med. Sci., 13: 311-316, 1998.
7. Willard, H. F., Durfy, S. J., Mahtani, M. M., Dorkins, H., Davies, K. E., and Williams, B. R. Regional localization of the TIMP gene on the human X chromosome. Extension of a conserved synteny and linkage group on proximal Xp. Hum. Genet., 81: 234-238, 1989.
8. Sementchenko, V. I., and Watson, D. K. Ets target genes: Past, present and future. Oncogene, 19: 6533-6548, 2000.
9. Sharrocks, A. D. Brown, A. L., Ling, Y., and Yates, P. R. The ETS-domain transcription factor family. Int. J. Biochem. Cell Biol., 29: 1371-1387, 1997.
10. Sapi, E., Flick, M. B., Rodov, S., and Kacinski, B. M. Ets-2 transdominant mutant abolishes anchorage-independent growth and macrophage colony-stimulating factor-stimulated invasion by BT20 breast carcinoma cells. Cancer Res., 58: 1027-1033, 1998.
11. Sementchenko, V. I., Schweinfest, C. W., Papas, T. S., and Watson, D. K. ETS2 function is required to maintain the transformed state of human prostate cancer cells. Oncogene, 17: 2883-2888, 1998.
12. Nozawa, M., Yomogida, K., Kanno, N., Nonomura, N., Miki, T., Okuyama, A., Nishimune, Y., and Nozaki, M. Prostate-specific transcription factor hPSE is translated only in normal prostate epithelial cells. Cancer Res., 60: 1348-1352, 2000.
13. Foos, G., Garcia-Ramirez, J. J., Galang, C. K., and Hauser, C. A. Elevated expression of Ets2 or distinct portions of Ets2 can reverse Ras-mediated cellular transformation. J. Biol. Chem., 273: 18871-18880, 1998.
14. Neznanov, N., Man, A. K., Yamamoto, H., Hauser, C. A., Cardiff, R. D., and Oshima, R. G. A single targeted Ets2 allele restricts development of mammary tumors in transgenic mice. Cancer Res., 59: 4242-4246, 1999.
15. Mavrothalassitis, G., and Ghysdael, J. Proteins of the ETS family with transcriptional repressor activity. Oncogene, 19: 6524-6532, 2000.
16. Shirasaki, F., Makhluf, H. A., LeRoy, C., Watson, D. K., and Trojanowska, M. Ets transcription factors cooperate with Sp1 to activate the human tenascin-C promoter. Oncogene, 18: 7755-7764, 1999.
17. Trojanowska, M. Ets factors and regulation of the extracellular matrix. Oncogene, 19: 6464-6471, 2000.
18. Buttice, G., Duterque-Coquillaud, M., Basuyaux, J. P., Carrere, S., Kurkinen, M., and Stehelin, D. Erg, an Ets-family member, differentially regulates human collagenase 1 (MMP1) and stromelysin 1 (MMP3) gene expression by physically interacting with the Fos/Jun complex. Oncogene, 13: 2297-2306, 1996.
19. Kai, H., Hisatsune, A., Chihara, T., Uto, A., Kokusho, A., Miyata, T., and Basbaum, C. Myeloid ELF-1-like factor up-regulates lysozyme transcription in epithelial cells. J. Biol. Chem., 274: 20098-20102, 1999.
20. Aryee, D. N., Petermann, R., Kos, K., Henn, T., Haas, O. A. and Kovar, H. Cloning of a novel human ELF-1-related ETS transcription factor, ELFR, its characterization and chromosomal assignment relative to ELF-1. Gene (Amst.), 210: 71-78, 1998.
21. Knox, J. D., Araujo, F. D., Bigey, P., Slack, A. D., Price, G. B., Zannis-Hadjopoulos, M., and Szyf, M. Inhibition of DNA methyltransferase inhibits DNA replication. J. Biol. Chem., 275: 17986-17990, 2000.
22. Milutinovic, S., Knox, J. D., and Szyf, M. DNA methyltransferase inhibition induces the transcription of the tumor suppressor p21(WAF1/CIP1/sdi1). J. Biol. Chem., 275: 6353-6359, 2000.
23. Llorens, A., Rodrigo, I., Lopez, B. L., Gonzalez, G. M., Lozano, E., Vinyals, A., Quintanilla, M., Cano, A., and Fabra, A. Down-regulation of E-cadherin in mouse skin carcinoma cells enhances a migratory and invasive phenotype linked to matrix metalloproteinase-9 gelatinase expression. Lab. Invest., 78: 1131-1142, 1998.
24. Mira, E., Manes, S., Lacalle, R. A., Marquez, G., and Martinez, A. C. Insulin-like growth factor I-triggered cell migration and invasion are mediated by matrix metalloproteinase-9. Endocrinology, 140: 1657-1664, 1999.
25. Bergers, G., Brekken, R., McMahon, G., Vu, T. H., Itoh, T., Tamaki, K., Tanzawa, K., Thorpe, P., Itohara, S., Werb, Z., and Hanahan, D. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat. Cell Biol., 2: 737-744, 2000.
26. Jiang, Y., Rom, W. N., Yie, T. A., Chi, C. X., and Tchou, W. K. Induction of tumor suppression and glandular differentiation of A549 lung carcinoma cells by dominant-negative IGF-I receptor. Oncogene, 18: 6071-6077, 1999.
27. Arenberg, D. A., Kunkel, S. L., Polverini, P. J., Glass, M., Burdick, M. D., and Strieter, R. M. Inhibition of interleukin-8 reduces tumorigenesis of human non-small cell lung cancer in SCID mice. J. Clin. Invest., 97: 2792-2802, 1996.
28. Iguchi, A., Kitajima, I., Yamakuchi, M., Ueno, S. Aikou, T., Kubo, T., Matsushima, K., Mukaida, N., and Maruyama, I. PEA3 and AP-1 are required for constitutive IL-8 gene expression in hepatoma cells. Biochem. Biophys. Res. Commun., 279: 166-171, 2000.
29. Kihara-Negishi, F. Yamamoto, H., Suzuki, M., Yamada, T., Sakurai, T., Tamura, T., and Oikawa, T. In vivo complex formation of PU.1 with HDAC1 associated with PU.1-mediated transcriptional repression. Oncogene, 20: 6039-6047, 2001.
30. 1 phase of the cell cycle. J. Biol. Chem., 276: 40528-40536, 2001.
31. Wasylyk, B., Hagman, J., and Gutierrez-Hartmann, A. Ets transcription factors: Nuclear effectors of the Ras-MAP-kinase signaling pathway. Trends Biochem. Sci., 23: 213-216, 1998.
32. Yang, B. S., Hauser, C. A., Henkel, G., Colman, M. S., Van Beveren, C., Stacey, K. J., Hume, D. A., Maki, R. A., and Ostrowski, M. C. Ras-mediated phosphorylation of a conserved threonine residue enhances the transactivation activities of c-Ets1 and c-Ets2. Mol. Cell. Biol., 16: 538-547, 1996.
33. Wasylyk, C., Bradford, A. P., Gutierrez-Hartmann, A., and Wasylyk, B. Conserved mechanisms of Ras regulation of evolutionary related transcription factors, Ets1 and Pointed P2. Oncogene, 14: 899-913, 1997.
34. Tugores, A., Le, J., Sorokina, I. Snijders, A. J., Duyao, M., Reddy, P. S., Carlee, L., Ronshaugen, M., Mushegian, A. Watanaskul, T., Chu, S., Buckler, A., Emtage, S., and McCormick, M. K. The epithelium-specific ETS protein EHF/ESE-3 is a context-dependent transcriptional repressor downstream of MAPK signaling cascades. J. Biol. Chem., 276: 20397-20406, 2001.
35. Mitchell, C. E., Belinsky, S. A., and Lechner, J. F. Detection and quantitation of mutant K-ras codon 12 restriction fragments by capillary electrophoresis. Anal. Biochem., 224: 148-153, 1995.
36. Foos, G., and Hauser, C. A. Altered Ets transcription factor activity in prostate tumor cells inhibits anchorage-independent growth, survival, and invasiveness. Oncogene, 19: 5507-5516, 2000.
37. Suzuki, H., Romani-Spica, V., Papas, T. S., and Bhat, N. K. Proc. Natl. Acad. Sci. USA, 92: 4442-4446, 1995.
38. Wasylyk, C., Maira, S. M., Sobieszczuk, P., and Wasylyk, B. Oncogene, 9: 3665-3673, 1994.
39. Czuwara-Ladykowska, J., Shirasaki, F., Jackers, P., Watson, D. K., and Trojanowska, M. Fli-1 inhibits collagen type 1 production in dermal fibroblasts via an Sp1-dependent pathway. J. Biol. Chem. 276: 20839-20848, 2001.